Anti-TSLP therapy reduces inflammation in moderate to severe asthma
SAN DIEGO — A fragment antibody against thymic stromal lymphopoietin was safe and effective in reducing airway inflammation among patients with asthma, according to a presentation at the American Thoracic Society International Conference.“Thymic stromal lymphopoietin (TSLP) is involved in chronic inflammatory disorders, including asthma and COPD,” Maria Belvisi, PhD, senior vice
Source: healio.com
